These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 19288753)
1. [Status quo of the researches on HSV vaccines]. Gao J; Lu JC; Huang YF Zhonghua Nan Ke Xue; 2009 Jan; 15(1):60-4. PubMed ID: 19288753 [TBL] [Abstract][Full Text] [Related]
2. [Herpes simplex virus vaccine studies: from past to present]. Us D Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting. Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350 [TBL] [Abstract][Full Text] [Related]
7. An update on short-course episodic and prevention therapies for herpes genitalis. Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886 [TBL] [Abstract][Full Text] [Related]
8. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2. Quenelle DC; Collins DJ; Marciani DJ; Kern ER Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model. Manservigi R; Boero A; Argnani R; Caselli E; Zucchini S; Miriagou V; Mavromara P; Cilli M; Grossi MP; Balboni PG; Cassai E Vaccine; 2005 Jan; 23(7):865-72. PubMed ID: 15603886 [TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus: benefit versus risk factors in immunization. zur Hausen H Dev Biol Stand; 1979; 43():373-9. PubMed ID: 230113 [TBL] [Abstract][Full Text] [Related]
12. The Holy Grail: immune control of human herpes simplex virus infection and disease. Cunningham AL; Mikloska Z Herpes; 2001 Mar; 8 Suppl 1():6A-10A. PubMed ID: 11867028 [TBL] [Abstract][Full Text] [Related]
13. Prospects for control of herpes simplex virus disease through immunization. Stanberry LR; Cunningham AL; Mindel A; Scott LL; Spruance SL; Aoki FY; Lacey CJ Clin Infect Dis; 2000 Mar; 30(3):549-66. PubMed ID: 10722443 [TBL] [Abstract][Full Text] [Related]
14. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge. Jamali A; Roostaee MH; Soleimanjahi H; Ghaderi Pakdel F; Bamdad T Comp Immunol Microbiol Infect Dis; 2007 Mar; 30(2):71-80. PubMed ID: 17126902 [TBL] [Abstract][Full Text] [Related]
15. Immunology of herpes simplex virus infection: relevance to herpes simplex virus vaccines and cervical cancer. Nahmias AJ; Shore SL; Kohl S; Starr SE; Ashman RB Cancer Res; 1976 Feb; 36(2 pt 2):836-44. PubMed ID: 766960 [TBL] [Abstract][Full Text] [Related]
16. Keratin, a dual role in herpes simplex virus pathogenesis. Friedman HM J Clin Virol; 2006 Jan; 35(1):103-5. PubMed ID: 15916917 [TBL] [Abstract][Full Text] [Related]
17. Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus. Ferenczy MW Curr Pharm Des; 2007; 13(19):1975-88. PubMed ID: 17627531 [TBL] [Abstract][Full Text] [Related]
18. Status of vaccine research and development of vaccines for herpes simplex virus. Johnston C; Gottlieb SL; Wald A Vaccine; 2016 Jun; 34(26):2948-2952. PubMed ID: 26973067 [TBL] [Abstract][Full Text] [Related]
19. The ongoing pursuit of a prophylactic HSV vaccine. Chung E; Sen J Rev Med Virol; 2012 Sep; 22(5):285-300. PubMed ID: 22396215 [TBL] [Abstract][Full Text] [Related]
20. [A kinetic study of gamma interferon production in herpes simplex virus-1 DNA prime-protein boost regimen comparing to DNA or subunit vaccination]. Arefian E; Bamdad T; Soleimanjahi H; Akhood MR; Parsania M; Ghaemi A Mol Biol (Mosk); 2009; 43(3):422-8. PubMed ID: 19548528 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]